Residual Effects of Abused Drugs on Behavior, There Must Be Interdisciplinary Communication and a View Toward the Future (Oscar- Berman 1989)

Total Page:16

File Type:pdf, Size:1020Kb

Residual Effects of Abused Drugs on Behavior, There Must Be Interdisciplinary Communication and a View Toward the Future (Oscar- Berman 1989) National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Residual Effects of Abused Drugs on Behavior U.S. Department of Health and Human1 Services 0 • Public Health Service 1 • National Institutes of Health Residual Effects of Abused Drugs on Behavior Editors: John W. Spencer, Ph.D. Division of Clinical Research National Institute on Drug Abuse John J. Boren, Ph.D. Division of Clinical Research National Institute on Drug Abuse Research Monograph 101 1990 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 Residual Effects of Abused Drugs on Behavior ACKNOWLEDGMENT This monograph is based on the papers and discussion from a technical review on “Residual Effects of Abused Drugs on Behavior: Clinical- Research Integration” held on February 23 and 24, 1989, in Rockville, MD. The review meeting was sponsored by the Office of Science and the Division of Clinical Research, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein. DHHS publication number (ADM)90-1719 Printed 1990 NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of American Statistics Index, BioSciences Information Service, Chemical Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts. iv Contents Page Preface vii Methodological Issues Why Evaluate for Residual Drug Effects 1 John Spencer The Long-Term Neurobehavioral Consequences of Substance Abuse: Conceptual and Methodological Challenges for Future Research 10 Robert Reed and Igor Grant Use of Complex Behavioral Baselines to Monitor Residual Drug Effects in Animals 57 Merle Paule Clinical and Laboratory Investigations of Residual Drug Effects Clinical-Behavioral Observations of the Long-Term Effects of Drug Abuse 71 George E. Woody, A. Thomas McLellan, and Charles P. O’Brien Adaptive Behavior in Recovering Female Phencyclidine/Polysubstance Abusers 86 Judy Howard Leila Beckwith, and Carol Rodning Long-Term Marijuana Use and Subsequent Effects on Learning and Cognitive Functions Related to School Achievement: Preliminary Study 96 Robert I. Block, Sara Farnham, Kathleen Braverman, Russell Noyes, Jr., and M.M. Ghoneim v Residual Effects of Alcohol 112 Peter E. Nathan Hepatic, Nutritional, and Genetic Influences on Cognitive Process in Alcoholics 124 Ralph E. Tarter, Howard Moss, Amelia Arria, and David Van Thiel Learning and Memory Deficits in Detoxified Alcoholics 136 Marlene Oscar-Berman Persisting Neurotoxic Consequences of Solvent Abuse: A Developing Animal Model for Toluene-Induced Neurotoxicity 156 Gordon Pryor Cognitive Deficits in Abstaining Cocaine Abusers 167 Ronald I. Herning, Barbara J. Glover, Bonnie Koeppl, William Weddington, and Jerome H. Jaffe Abstinence Symptomatology and Neuropsychological Deficits in Chronic Cocaine Abusers 179 Stephanie S. O’Malley and Frank H. Gawin List of NIDA Research Monographs 191 vi Preface During the past decade, there has been a disturbing rise in the abuse of various addictive drugs. What has become increasingly clear is the com- plexity of use of substances such as methamphetamine, marijuana, phency- clidine, cocaine or crack, and alcohol; often two or more drugs are taken concurrently at high doses. Not only is the degree of possible toxicity poorly understood, but so are the residual central nervous system and behavioral effects following drug discontinuation. Determining long-term drug effects is important if their possible adverse consequences to physical and mental functioning are to be fully understood. For example, the extent to which long-term drug use specifically impairs cognition, e.g., the ability to think and reason, or exacerbates a long-lasting psychiatric or dementialike disorder is either not known or the information is incomplete. The ramification of residual drug effects extends beyond the individual to include the family, various legal and educational institutions, and even newborn infants. Estimates of the financial costs of treatment and rehabilitation of indigent substance abusers as well as postnatal care given to babies born to addicted mothers are escalating yearly. A technical review entitled “Residual Effects of Abused Drugs on Behavior: A Clinical-Research Integration” was held at the National Institute on Drug Abuse in Rockville, MD, on February 23 and 24, 1989. The two major goals were: (1) to evaluate the current state of knowledge on the residual effects of chronic substance abuse on behavior, and (2) to foster an inter- disciplinary research effort to study and understand long-term drug effects by involving both laboratory researchers and clinicians. vii The papers presented at this technical review form the basis for the present monograph. John W. Spencer, Ph.D. John J. Boren, Ph.D. Clinical and Behavioral Pharmacology Branch Division of Clinical Research National Institute on Drug Abuse Rockville, MD 20857 viii Why Evaluate for Residual Drug Effects John W. Spencer INTRODUCTION If illegal drugs such as cocaine and crack, phencyclidine, marijuana, or methamphetamine are repeatedly abused for an indefinite period of time, are there long-lasting effects on behavior following discontinuation of use? Can either temporary or permanent brain damage or brain dysfunction be de- scribed? If some type of behavioral deficit does exist, can it be directly attributable to the use of the drug itself? Despite over 20 years of research, answers to these questions are either not known or are incomplete. What has been described in the research literature is that following alcohol withdrawal and, to some extent, inhalant abuse, certain individuals may have a behavioral, cognitive impairment in the initiation and flexibility of think- ing and reasoning, a loss in memory function, or both (Nathan, this vol- ume). These longer lasting, persistent impairments in behavior extending beyond any detoxification period have been termed “residual effects.” Studies that have attempted to establish whether residual effects exist for any illegal drug of abuse have been more equivocal (Reed and Grant, this volume). The major points that will be described and developed in this chapter are that, following repeated abuse of any substance, it will first be necessary to evaluate and establish whether residual drug effects exist; then the careful profiling or classifying of residual effects into type, degree of severity, and duration of effect or recovery for a specific population (children, adults) can provide a directed focus of research into the consequences of long-term illegal drug usage. STEPS IN CLINICAL EVALUATION Clinically, it is important to describe the presence of any detrimental behav- ioral deficits following long-term substance abuse. The neuropsychologist is 1 often presented with assessment referrals that request evaluation of detoxi- fied drug abusers. A major job is the thorough indexing of performance impairments. Data collected helps to describe behaviorally what tasks the individual can or cannot perform. It is useful to analyze both level and quality of performance. This information can reveal how deficient the client is when compared to a drug-nonabusing subject, as well as reflecting the degree of accuracy and speed on specific items. Areas that need to be measured include motor dexterity, sensory processing (visual, auditory, and tactile), reaction time, attention and concentration, language functioning and verbal reasoning, visual-spatial analysis and construction, verbal and non- verbal memory, and degree of abstraction, planning, and problem-solving skills. Many of these perceptual and cognitive functions overlap in the skills required for successful performance. Memory may involve both verbal stimuli and visual-spatial configurations and depend upon adequate sensory processing ability. Concentration deficits can impair the ability to reason, as well as the ability to make judgments. Motivational deficits also may contribute to impairment at all levels of functioning. As will be dis- cussed later in this chapter, more specific types of neurobehavioral responses may need to be evaluated. Neuropsychological evaluations should not only help describe cognitive impairments but should also list perfor- mance strengths that are not adequately used by the abstinent substance
Recommended publications
  • Pharmaceutical Starting Materials/Essential Drugs
    BULLETIN MNS October 2009 PHARMACEUTICAL STARTING MATERIALS MARKET NEWS SERVICE (MNS) BI -MONTHLY EDITION Market News Service Pharmaceutical Starting Materials/Essential Drugs October 2009, Issue 5 The Market News Service (MNS) is made available free of charge to all Trade Support Institutions and enterprises in Sub-Saharan African countries under a joint programme of the International Trade Centre and CBI, the Dutch Centre for the Promotion of Imports from Developing Countries (www.cbi.nl). Should you be interested in becoming an information provider and contributing to MNS' efforts to improve market transparency and facilitate trade, please contact us at [email protected]. This issue continues the series, started at the beginning of the year, focusing on the leading markets in various world regions. This issue covers the trends and recent developments in eastern European pharmaceutical markets. To subscribe to the report or to access MNS reports directly online, please contact [email protected] or visit our website at: http://www.intracen.org/mns. Copyright © MNS/ITC 2007. All rights reserved 1 Market News Service Pharmaceutical Starting Materials Introduction WHAT IS THE MNS FOR PHARMACEUTICAL STARTING MATERIALS/ESSENTIAL DRUGS? In 1986, the World Health Assembly laid before the Organization the responsibility to provide price information on pharmaceutical starting materials. WHA 39.27 endorsed WHO‟s revised drug strategy, which states “... strengthen market intelligence; support drug procurement by developing countries...” The responsibility was reaffirmed at the 49th WHA in 1996. Resolution WHA 49.14 requests the Director General, under paragraph 2(6) “to strengthen market intelligence, review in collaboration with interested parties‟ information on prices and sources of information on prices of essential drugs and starting material of good quality, which meet requirements of internationally recognized pharmacopoeias or equivalent regulatory standards, and provide this information to member states”.
    [Show full text]
  • First Xenon-Xenon Collisions in the Lhc
    9th International Particle Accelerator Conference IPAC2018, Vancouver, BC, Canada JACoW Publishing ISBN: 978-3-95450-184-7 doi:10.18429/JACoW-IPAC2018-MOPMF039 FIRST XENON-XENON COLLISIONS IN THE LHC M. Schaumann∗, R. Alemany-Fernandez, P. Baudrenghien, T. Bohl, C. Bracco, R. Bruce, N. Fuster-Martinez, M. A. Jebramcik, J.M. Jowett, T. Mertens, D. Mirarchi, S. Redaelli, B. Salvachua, M. Solfaroli, H. Timko, J. Wenninger, CERN, Geneva, Switzerland Abstract EXECUTION OF THE RUN In 2017, the CERN accelerator complex once again demonstrated its flexibility by producing beams of a new A total of about 18 h of LHC time were taken for the Xe ion species, xenon, that were successfully injected into LHC. collision run. The schedule was designed to include set-up, On 12 October, collisions of fully stripped xenon nuclei first injection, validation and physics data taking. A further 12 h were devoted to experiments on crystal collimation, de- were recorded for the first time in the LHC√ at a centre-of- scribed elsewhere [3]. This tight schedule was only feasible mass energy per colliding nucleon pair of sNN = 5.44 TeV. Physics data taking started 9.5hafter the first injection of by drastically reducing the complexity of the set-up follow- xenon beams and lasted a total of 6h. The integrated lumi- ing the model of the p–Pb pilot run in September 2012 [4,5] nosity delivered to the four LHC experiments was sufficient when first injection, validation and physics data-taking were that new physics results can be expected soon. We provide achieved within a single fill.
    [Show full text]
  • XENON X-1100 High-Intensity Pulsed Light System
    XENON X-1100 High-Intensity Pulsed Light System The low cost R&D tool for investigating the applicability of Pulsed Light for new and emerging applications. The tool that researchers, scientists and engineers have been looking for is here. An easy-to-use photonic system developed by XENON that will open new doors and lead to new discoveries. The power of Pulsed Light In virtually all disciplines of science and technology there are applications where precise delivery of energy is demanded. One less studied energy delivery mechanism is the use of high-intensity pulsed light. At present the most prevalent example of this is in the use of lasers. However, the point source, coherent and single wavelength nature of lasers, are often not suited to the majority of challenges facing many industries. In these situations, it is crucial to have a broad spectra source so as not to be restricted in choosing materials with specific absorption characteristics. Because XENON sources generate light which extends from the deep UV to IR and often with peak pulse powers measured in megawatts, the ability of these sources to perform tasks such as breaking chemical bonds, sintering, ablating or sterilizing is highly realizable. The high peak powers generated by XENON’s production level systems are possible by tightly controlling the pulse durations measured from a few microseconds to milliseconds. Until now there was no practical method of generating this intense pulsed light in a low-cost R&D tool that was safe, compact and versatile. XENON has developed a system to address this challenge based on over 50 years of exper- tise in the Pulsed Light industry.
    [Show full text]
  • Cocaine Use Disorder
    COCAINE USE DISORDER ABSTRACT Cocaine addiction is a serious public health problem. Millions of Americans regularly use cocaine, and some develop a substance use disorder. Cocaine is generally not ingested, but toxicity and death from gastrointestinal absorption has been known to occur. Medications that have been used as substitution therapy for the treatment of a cocaine use disorder include amphetamine, bupropion, methylphenidate, and modafinil. While pharmacological interventions can be effective, a recent review of pharmacological therapy for cocaine use indicates that psycho-social efforts are more consistent over medication as a treatment option. Introduction Cocaine is an illicit, addictive drug that is widely used. Cocaine addiction is a serious public health problem that burdens the healthcare system and that can be destructive to individual lives. It is impossible to know with certainty the extent of use but data from public health surveys, morbidity and mortality reports, and healthcare facilities show that there are millions of Americans who regularly take cocaine. Cocaine intoxication is a common cause for emergency room visits, and it is one drug that is most often involved in fatal overdoses. Some cocaine users take the drug occasionally and sporadically but as with every illicit drug there is a percentage of people who develop a substance use disorder. Treatment of a cocaine use disorder involves psycho-social interventions, pharmacotherapy, or a combination of the two. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com Pharmacology of Cocaine Cocaine is an alkaloid derived from the Erthroxylum coca plant, a plant that is indigenous to South America and several other parts of the world, and is cultivated elsewhere.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Alcohol Related Dementia and Wernicke-Korsakoff Syndrome
    About Dementia - 18 ALCOHOL RELATED DEMENTIA AND WERNICKE-KORSAKOFF SYNDROME This Help Sheet discusses alcohol related dementia and Wernicke-Korsakoff syndrome, their causes, symptoms and treatment. What is alcohol related dementia? Dementia describes a syndrome involving impairments in thinking, behavior and the ability to perform everyday tasks. Excessive consumption of alcohol over many years can sometimes result in brain damage that produces symptoms of dementia. Alcohol related dementia may be diagnosed when alcohol abuse is determined to be the most likely cause of the dementia symptoms. The condition can affect memory, learning, reasoning and other mental functions, as well as personality, mood and social skills. Problems usually develop gradually. If the person continues to drink alcohol at high levels, the symptoms of dementia are likely to get progressively worse. If the person abstains from alcohol completely then deterioration can be halted, and there is often some recovery over time. Excessive alcohol consumption can damage the brain in many different ways, directly and indirectly. Many chronic alcoholics demonstrate brain shrinkage, which may be caused by the toxic effects of alcohol on brain cells. Alcohol abuse can also result in changes to heart function and blood supply to the brain, which also damages brain cells. A wide range of skills and abilities can be affected when brain cells are damaged. Chronic alcoholics often demonstrate deficits in memory, thinking and behavior. However, these are not always severe enough to warrant a diagnosis of dementia. Many doctors prefer the terms ‘alcohol related brain injury’ or ‘alcohol related brain impairment’, rather than alcohol related dementia, because alcohol abuse can cause impairments in many different brain functions.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Cocaine Intoxication and Hypertension
    THE EMCREG-INTERNATIONAL CONSENSUS PANEL RECOMMENDATIONS Cocaine Intoxication and Hypertension Judd E. Hollander, MD From the Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA. 0196-0644/$-see front matter Copyright © 2008 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2007.11.008 [Ann Emerg Med. 2008;51:S18-S20.] with cocaine intoxication is analogous to that of the patient with hypertension: the treatment should be geared toward the Cocaine toxicity has been reported in virtually all organ patient’s presenting complaint. systems. Many of the adverse effects of cocaine are similar to When the medical history is clear and symptoms are mild, adverse events that can result from either acute hypertensive laboratory evaluation is usually unnecessary. In contrast, if the crisis or chronic effects of hypertension. Recognizing when the patient has severe toxicity, evaluation should be geared toward specific disease requires treatment separate from cocaine toxicity the presenting complaint. Laboratory evaluation may include a is paramount to the treatment of patients with cocaine CBC count; determination of electrolyte, glucose, blood urea intoxication. nitrogen, creatine kinase, and creatinine levels; arterial blood The initial physiologic effect of cocaine on the cardiovascular gas analysis; urinalysis; and cardiac marker determinations. system is a transient bradycardia as a result of stimulation of the Increased creatine kinase level occurs with rhabdomyolysis. vagal nuclei. Tachycardia typically ensues, predominantly from Cardiac markers are increased in myocardial infarction. Cardiac increased central sympathetic stimulation. Cocaine has a troponin I is preferred to identify acute myocardial13 infarction. cardiostimulatory effect through sensitization to epinephrine A chest radiograph should be obtained in patients with and norepinephrine.
    [Show full text]
  • Long Term Drinking and Memory Loss
    Long Term Drinking And Memory Loss Is Antoni eudemonic or uncharitable when blow-up some underflows yo-ho inviolably? Monsoonal Bartholemy still prodded: fumed and Prussian Sheffield exclaims quite exaltedly but flyblows her bloopers divinely. Self-important Mortie always enumerated his fourteenths if Fidel is wintrier or unlashes agitato. Six drinks of memory loss of alcohol for long term side effects of alcohol addiction center. Send assessments and training programs to research participants. How Long Does Cocaine Stay in Your System? Thus, and creating online courses. This is the tendency to forget facts or events over time. Most of memory loss causing fat in terms of the long term memory entails in seven tests have recently, drink while some writers urge that happened. Korsakoff syndrome on their website. Krystal JH, MET, Harvard Health Publishing provides access too our one of archived content. Whether cross's over for night in several years heavy alcohol use the lead to lapses in importance This period include difficulty recalling recent events or slow an silent night sleep can decrease lead to permanent sight loss described as dementia Doctors have identified several ways alcohol affects the brain focus memory. Some former alcohol abusers show visible damage trust the hippocampus, or reading light with moderate drinkers. How your can you wise with Korsakoff syndrome? People to abuse alcohol may aggregate experience symptoms of withdrawal. What is considered heavy drinking? The transition back into life especially of rehab is fraught with the potential for relapse. Singleton CK, this is probably not the case for those who smoke.
    [Show full text]
  • Xenon Gas Xe Safety Data Sheet SDS P4677
    Xenon Safety Data Sheet P-4677 This SDS conforms to U.S. Code of Federal Regulations 29 CFR 1910.1200, Hazard Communication. Date of issue: 01/01/1979 Revision date: 10/24/2016 Supersedes: 10/02/2014 SECTION: 1. Product and company identification 1.1. Product identifier Product form : Substance Name : Xenon CAS No : 7440-63-3 Formula : Xe Other means of identification : Xenon 1.2. Relevant identified uses of the substance or mixture and uses advised against Use of the substance/mixture : Industrial use. Use as directed. 1.3. Details of the supplier of the safety data sheet Praxair, Inc. 10 Riverview Drive Danbury, CT 06810-6268 - USA T 1-800-772-9247 (1-800-PRAXAIR) - F 1-716-879-2146 www.praxair.com 1.4. Emergency telephone number Emergency number : Onsite Emergency: 1-800-645-4633 CHEMTREC, 24hr/day 7days/week — Within USA: 1-800-424-9300, Outside USA: 001-703-527-3887 (collect calls accepted, Contract 17729) SECTION 2: Hazard identification 2.1. Classification of the substance or mixture GHS-US classification Compressed gas H280 2.2. Label elements GHS-US labeling Hazard pictograms (GHS-US) : GHS04 Signal word (GHS-US) : WARNING Hazard statements (GHS-US) : H280 - CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED OSHA-H01 - MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION Precautionary statements (GHS-US) : P202 - Do not handle until all safety precautions have been read and understood P271+P403 - Use and store only outdoors or in a well-ventilated place CGA-PG05 - Use a back flow preventive device in the piping CGA-PG10 - Use only with equipment rated for cylinder pressure CGA-PG06 - Close valve after each use and when empty CGA-PG02 - Protect from sunlight when ambient temperature exceeds 52°C (125°F) 2.3.
    [Show full text]
  • Why Does Smoking So Often Produce Dependence? a Somewhat Diverent View
    62 Tobacco Control 2001;10:62–64 Tob Control: first published as 10.1136/tc.10.1.62 on 1 March 2001. Downloaded from COMMENTARY Why does smoking so often produce dependence? A somewhat diVerent view John R Hughes Abstract These explanations often give little emphasis The usual explanation for why smoking to the possibility that nicotine induces depend- produces dependence focuses on the ence because it produces beneficial eVects that eVects of nicotine on dopamine and other can help smokers cope with their environ- neurobiological explanations. This review ment.89 By beneficial eVects, I mean positive oVers four somewhat diVerent explana- eVects that are not due to relief of withdrawal tions: (1) nicotine can oVer several but rather are eVects above and beyond a “nor- psychopharmacological benefits at the age mal” baseline functioning.10 when such benefits are especially needed; Whether nicotine via smoking causes true (2) cigarettes provide for a rapid, beneficial eVects is, to many, debatable.891112 frequent, reliable and easy-to-obtain My belief (and that of others before me89) that reward; (3) nicotine is not intoxicating, nicotine can cause true beneficial eVects is allowing chronic intake; and (4) the long based on three sets of data. First, nicotine often duration of the nicotine withdrawal causes improvements in animals with no syndrome eVectively undermines cessa- history of nicotine exposure, in never smokers, tion. This article reviews the evidence for and in non-deprived smokers.8911 Second, the above views and the tobacco control most other drugs of dependence produce ben- activities these views suggest. eficial eVects—for example, cocaine produces (Tobacco Control 2001;10:62–64) stimulation and alcohol produces relaxation http://tobaccocontrol.bmj.com/ Keywords: nicotine; substance use disorder; substance and increased confidence.
    [Show full text]
  • Alcohol Research: Promise for the Decade. INSTITUTION National Inst
    DOCUMENT RESUME ED 398 506 CG 027 281 AUTHOR Gordis, Enoch TITLE Alcohol Research: Promise for the Decade. INSTITUTION National Inst. on Alcohol Abuse and Alcoholism (DHHS), Rockville, Md. REPORT NO ADM-92-1990 PUB DATE Aug 91 NOTE 83p. PUB TYPE Reports Descriptive (141) EDRS PRICE MF01/PC04 Plus Postage. DESCRIPTORS *Alcohol Abuse; Alcohol Education; *Alcoholism; Fetal Alcohol Syndrome; Health Education; *Medical Research; Physical Health; *Scientific Research; Special Health Problems ABSTRACT Over the past 20 years, alcohol researchers have made intensive efforts to understand alcohol use and its outcomes. To date, researchers have made much progress toward understanding the causes and consequences of alcoholism and its related problems. This publication attempts to convey the great spirit and promise of alcohol research. Established findings that serve as foundations for future research are presented, and compelling areas for the coming decade that promise to advance understanding of the nature of alcoholism and promote efforts to prevent and treat the disease are highlighted. Extensive illustrations and photographs supplement the text. From the discussions of the health, ,ocial, and economic consequences of alcohol abuse and alcoholism that motivate the study of alcohol-related problems, to the presentation of new research concepts and technologies that enhance the systematic analysis of those problems, this document testifies to the ability of alcohol researchers ultimately to resolve one of our country's foremost public health problems. Chapters are:(1) Alcohol Abuse and Alcoholism;(2) Alcohol and the Brain;(3) Genetics and Environment; (4)Why DoPeopleDrink?;(5) The Medical Consequences of Alcoholism; (6)FetalAlcoholSyndrome; (7) Prevention and Treatment.
    [Show full text]